Brycen Gray and Ben Price COVID–19 Neurological Impact Act

Hozzl · 2022-12-30T07:33:59Z

Explore the details of House Bill 5772 Brycen Gray and Ben Price COVID–19 Neurological Impact Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

12/30/2022, 7:33 AM

Summary of Bill HR 5772

Bill 117 HR 5772, also known as the Brycen Gray and Ben Price COVID-19 Neurological Impact Act, is a piece of legislation introduced in the US Congress. The purpose of this bill is to address the neurological impact of COVID-19 on individuals who have contracted the virus.

The bill is named after Brycen Gray and Ben Price, two individuals who have experienced neurological symptoms as a result of COVID-19. The legislation aims to provide funding for research into the neurological effects of the virus, as well as support for individuals who are suffering from these symptoms.

Specifically, the bill calls for the establishment of a task force to study the neurological impact of COVID-19 and develop recommendations for treatment and support for affected individuals. It also includes provisions for funding research into the long-term effects of the virus on the brain and nervous system. Overall, the Brycen Gray and Ben Price COVID-19 Neurological Impact Act seeks to address a critical aspect of the ongoing COVID-19 pandemic and provide support for individuals who are experiencing neurological symptoms as a result of the virus.

Congressional Summary of HR 5772

Brycen Gray and Ben Price COVID-19 Neurological Impact Act

This bill authorizes grants and requires other activities to address neurological and psychiatric illnesses associated with COVID-19 infection.

Specifically, the National Science Foundation may award competitive grants for multidisciplinary research on such illnesses.

In addition, the White House Office of Science and Technology Policy must establish a temporary interagency working group to coordinate relevant federal programs, data collection, and other activities focused on neurological and psychiatric illnesses associated with COVID-19 infection. The working group must also engage with researchers and nonfederal stakeholders to ensure the sharing and dissemination of relevant research, information, and best practices pertaining to those illnesses. The working group terminates after five years.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 5772

Bill HR 5772 is currently in the status of Bill Introduced since October 28, 2021. Bill HR 5772 was introduced during Congress 117 and was introduced to the House on October 28, 2021. Bill HR 5772's most recent activity was Referred to the Subcommittee on Health. as of October 29, 2021

Bipartisan Support of Bill HR 5772

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 5772

Primary Policy Focus

Health

Potential Impact Areas

- Cardiovascular and respiratory health

- Child health

- Emergency medical services and trauma care

- Executive Office of the President

- Executive agency funding and structure

- Health information and medical records

- Infectious and parasitic diseases

- Medical research

- Medical tests and diagnostic methods

- Mental health

- Neurological disorders

- Research administration and funding

Alternate Title(s) of Bill HR 5772

Brycen Gray and Ben Price COVID–19 Neurological Impact Act

To authorize the Director of the National Science Foundation to award grants to support research on neurological and psychiatric illnesses associated with COVID-19 infection, and for other purposes.